After-Hours Movers 12/12: Biogen (BIIB) Lower on Failed Sale, Martek (MATK) and ADC (ADCT) Up on Earnings
Get Alerts BIIB Hot Sheet
Join SI Premium – FREE
StreetInsider.com After-Hours Movers:
Biogen Idec Inc. (NASDAQ: BIIB) 27% LOWER; said The Board of Directors of complated the review of strategic alternatives - the company will continue on its present course as an independent Company. Biogen Idec did not receive any definitive offers to purchase the Company.
Martek Biosciences Corporation (Nasdaq: MATK) 14% HIGHER; reported Q4 EPS of $0.23, 3 cents better than the analysts estimates of $0.20. Revenues for the quarter were $82 million, versus the consensus of $78.44 million.
Amtech Systems (Nasdaq: ASYS) 14% LOWER; reported Q4 EPS of $0.17, 2 cents better than the analyst estimate of $0.15. Revenues for the quarter were $13.1 million, versus the consensus of $13.33 million. Amtech expects FY08 revenues to be in the range of $65 to $75 million, versus the consensus of $73.5 million and Q1 revenues of $11 to $12 million, versus the consensus of $13.84 million.
Select Comfort Corporation (NASDAQ: SCSS) 12% LOWER; said, "while sales trends continued to improve through and including Black Friday, they remained below expectations and have since softened at a time when we had projected continued improvement. Given the leverage in the business model, our current outlook is that sales and profits will fall short of our previous guidance."
Elan Corp. plc (NYSE: ELN) 9% LOWER; TYSABRI partner Biogen Idec doesn't find a buyer.
ADC Telecommunications (Nasdaq: ADCT) 9% HIGHER; reported Q4 EPS of $0.30, ex-items, 8 cents better than the analysts estimates of $0.22. Revenues for the quarter were $330 million, versus the consensus of $318.37 million. ADC sees FY08 revenues $1.45 to $1.475 billion, versus the consensus of $1.39 billion. FY08 GAAP EPS are expected to be in the range of $0.68 to $0.78. Martek Biosciences sees Q1 EPS of $0.21-$0.23, versus the consensus of $0.17. Sees Q1 revenues of $79-$83 million, versus the consensus of $77.3 million.
Security Capital Assurance Ltd. (NYSE: SCA) 6% LOWER; continues today 21% drop related to Fitch Ratings' placing the company's subsidiaries XL Capital Assurance Inc. and XL Financial Assurance Ltd on Rating Watch Negative.
For Real-Time Market Moving News Sign Up for StreetInsider.com Premium - FREE TRIAL
Biogen Idec Inc. (NASDAQ: BIIB) 27% LOWER; said The Board of Directors of complated the review of strategic alternatives - the company will continue on its present course as an independent Company. Biogen Idec did not receive any definitive offers to purchase the Company.
Martek Biosciences Corporation (Nasdaq: MATK) 14% HIGHER; reported Q4 EPS of $0.23, 3 cents better than the analysts estimates of $0.20. Revenues for the quarter were $82 million, versus the consensus of $78.44 million.
Amtech Systems (Nasdaq: ASYS) 14% LOWER; reported Q4 EPS of $0.17, 2 cents better than the analyst estimate of $0.15. Revenues for the quarter were $13.1 million, versus the consensus of $13.33 million. Amtech expects FY08 revenues to be in the range of $65 to $75 million, versus the consensus of $73.5 million and Q1 revenues of $11 to $12 million, versus the consensus of $13.84 million.
Select Comfort Corporation (NASDAQ: SCSS) 12% LOWER; said, "while sales trends continued to improve through and including Black Friday, they remained below expectations and have since softened at a time when we had projected continued improvement. Given the leverage in the business model, our current outlook is that sales and profits will fall short of our previous guidance."
Elan Corp. plc (NYSE: ELN) 9% LOWER; TYSABRI partner Biogen Idec doesn't find a buyer.
ADC Telecommunications (Nasdaq: ADCT) 9% HIGHER; reported Q4 EPS of $0.30, ex-items, 8 cents better than the analysts estimates of $0.22. Revenues for the quarter were $330 million, versus the consensus of $318.37 million. ADC sees FY08 revenues $1.45 to $1.475 billion, versus the consensus of $1.39 billion. FY08 GAAP EPS are expected to be in the range of $0.68 to $0.78. Martek Biosciences sees Q1 EPS of $0.21-$0.23, versus the consensus of $0.17. Sees Q1 revenues of $79-$83 million, versus the consensus of $77.3 million.
Security Capital Assurance Ltd. (NYSE: SCA) 6% LOWER; continues today 21% drop related to Fitch Ratings' placing the company's subsidiaries XL Capital Assurance Inc. and XL Financial Assurance Ltd on Rating Watch Negative.
For Real-Time Market Moving News Sign Up for StreetInsider.com Premium - FREE TRIAL
You May Also Be Interested In
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell signs major custom silicon deal with Google, sell-side comments
- Goldman Sachs reviews US consumer staples sales data for August from NielsenIQ
Create E-mail Alert Related Categories
General News, Special ReportsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share